Company Filing History:
Years Active: 2025
Title: Alanson Girton: Innovator in Influenza Vaccine Development
Introduction
Alanson Girton is a notable inventor based in Frederick, MD (US). He has made significant contributions to the field of virology, particularly in the development of innovative vaccine platforms for influenza.
Latest Patents
Girton holds a patent for "Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same." This invention provides a modified influenza A virus (IAV) that includes at least one artificial gene segment with a duplicated packaging signal. The result is a replication-competent and avirulent IAV that, when co-infected with a wild type virus, leads to segment exchange. This process compromises the spread of both viruses and offers methods for using the IAVs in the treatment and prevention of influenza-related diseases. He has 1 patent to his name.
Career Highlights
Alanson Girton is affiliated with Duke University, where he continues to advance research in the field of infectious diseases. His work has the potential to significantly impact public health by improving vaccine efficacy against influenza.
Collaborations
Girton has collaborated with notable colleagues such as Nicholas Scott Heaton and Alfred Theodore Harding. Their combined expertise contributes to the innovative research being conducted at Duke University.
Conclusion
Alanson Girton's work in developing a novel influenza vaccine platform showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against influenza-related diseases.